Boehringer Ingelheim Agrees to Pay $650 in Pradaxa Settlements
Pradaxa manufacturer Boehringer Ingelheim announced last month that it has agreed to pay $650 million to settle thousands of lawsuits involving the blood thinning medication. More than 4,000 cases against the company are currently pending in state and federal courts. The settlement will likely resolve most of them.
Plaintiffs accuse Boehringer of causing patients to suffer severe and sometimes even fatal bleeding incidents. They claim they were not given a sufficient warning of the potentially fatal bleeding events and doctors were not provided with an adequate reversal agent to stop the blood thinning effects of the drug.
Pradaxa is a blood-thinning medication used to decrease the risk of stroke and blood clots in patients with non-valvular atrial fibrillation. It an anticoagulant, a substance that prevents blood clots. Pradaxa is the first new treatment alternative to warfarin (Coumadin), in almost 60 years.
Pradaxa settlement cash advance
LawStreet Capital is a direct lender providing Pradaxa settlement loans to plaintiffs awaiting compensation from Boehringer Ingelheim. We offer both pre-settlement and post-settlement funding to help you make ends meet until you’ve received the payment you deserve for the damages you’ve sustained from taking Pradaxa.
Pre-settlement funding is awarded before a decision has been reached on your case, while post-settlement funding is offered to help bridge the gap between reaching a settlement and receiving the payment you’re entitled to.
Boehringer stands behind Pradaxa
Boehringer issued a statement saying the company continues to stand behind the safety and efficacy of the drug and continues to believe the lawsuits lack merit, but that settling the case allows them to move forward.
“Time and again, the benefits and safety of Pradaxa have been confirmed,” said Desiree Ralls-Morrison, senior vice president and general counsel of Boehringer Ingelheim USA. “BI stands resolutely behind PRADAXA and believed from the outset that the plaintiffs’ claims lacked merit. Notwithstanding our strong belief that we would prevail in these lawsuits, this settlement allows BI to avoid the distraction and uncertainty of lengthy litigation and focus on our mission of improving patients’ lives.”
The company continues the statement by praising its employees who “worked for years to research, develop and offer to patients such an important medication as Pradaxa.”
“This settlement does not change the facts about PRADAXA or its importance to patients. From the time PRADAXA launched, BI properly advised doctors and patients about its benefits and safety, working closely with FDA, European Medicines Agency (EMA) and other regulators to ensure doctors and patients had the information they needed,” said Ralls-Morrison.
Pradaxa settlement loan
The litigation process can take years to make it through the courts, but you may need your Pradaxa settlement funding now. LawStreet Capital assumes all risk, so you only repay the Pradaxa settlement loan if you win or settle your claim. Our risk-free terms and conditions are paired with the most competitive interest rates on the market. Once you’re approved for funding, we’ll place a cash advance in your bank account fast — often within 24 hours.
It is important to note that legal funding isn’t for everyone ─if you’re expecting a verdict soon or aren’t having trouble getting by without the settlement you’re owed, this may not be your most lucrative option. To find out more about Pradaxa lawsuit funding, contact LawStreet Capital today toll-free at 1.866.FUND.662.
- The New York Times, $650 Million to Settle Blood Thinner Lawsuits http://www.nytimes.com/2014/05/29/business/international/german-drug-company-to-pay-650-million-to-settle-blood-thinner-lawsuits.html?_r=0
- Bloomberg, Boehringer Pays $650 Million to End Blood Thinner Cases http://www.bloomberg.com/news/2014-05-28/boehringer-pays-650-million-to-end-blood-thinner-cases.html
- Boehringer Ingelheim, Boehringer Ingelheim Announces Comprehensive Settlement of U.S. Pradaxa Litigation http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/05-28-14-boehringer-ingelheim-announces-comprehensive-settlement-of-US-pradaxa-dabigatran-etexilate-mesylate-litigation.html